Psyence Biomedical Ltd. Warrant (PBMWW) Stock Price
PBMWWStock
$0.03
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta-0.15
PBMWW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)29.37%
Price vs S&P 500 (4W)-9.26%
VGM Score81.25
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PBMWWPsyence Biomedical Ltd. Warrant | — | — | A | $0.03 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Psyence Biomedical Ltd. Warrant
Psyence Biomedical develops natural psilocybin products for treating psychological trauma and mental health conditions in palliative care, currently advancing candidates through clinical trials. The company operates a federally licensed cultivation facility in Southern Africa, producing and exporting psilocybin for standardized pharmaceutical processing by international partners. This positions the company at the intersection of emerging psychedelic therapeutics and regulated mental health treatment markets.